Be ready to expand your knowledge at the largest Endocannabinoid Medicine Congress in the world
It is the world’s leading and largest medical congress on endocannabinoid medicine. The congress is organized by the WeCann Academy, international reference in medical education in this field.
WeCann Summit is a perfect combination of high quality content, curated in cooperation with the IACM, the latest research in the field, renowned international figures from around the globe, an inspired and motivated medical community and an elegant and pleasant atmosphere.
This congress has become the official meeting point for the world’s leading experts in this topic and the main industries in the sector.
It is exclusive for physicians, from all specialties and practice areas.
In 2023, the WeCann Summit brought together more than 1,300 doctors from more than 50 specialties and areas of practice.
Colleagues from all Brazilian states and several countries attended the first edition of the WeCann Summit, learning and exchanging experiences to update their knowledge and achieve better results for their patients.
It is impossible to remain unaware of this scientific movement. There are more than 35,000 scientific articles on Pubmed approaching the therapeutic potential of cannabinoid derivatives.
Modern countries such as Germany, Israel and Canada have already incorporated cannabis-based therapies into their health systems.
The pharmaceutical industry is working hard to produce and license cannabis-based products. In Brazil we have already more than 30 products registered by the National Health Surveillance Agency (ANVISA).
Most importantly, there are millions of patients with severe, refractory and disabling disorders who could benefit from endocannabinoid system-targeting treatments.
Kirsten Müller-Vahl is an expert in neurology and adult psychiatry, currently holding a professorship in psychiatry at the Department of Psychiatry, Hannover Medical School in Germany. With a research career spanning over twenty years, Müller-Vahl has focused on investigating the therapeutic effects of medical cannabis in the treatment of tics, particularly in more than 1500 patients with Tourette syndrome and other psychiatric disorders.
Müller-Vahl serves as the principal investigator in numerous studies, which have received funding from prestigious institutions such as the German Research Support Society, the German Federal Ministry of Education and Research, the European Union, and industry sponsors. These studies explore the efficacy of cannabis-based medicines and cannabinoid modulators. Additionally, Müller-Vahl actively contributes to the scientific community as a member of the scientific advisory board of the Tourette Society Germany and as a board member of the International Alliance for Cannabinoid Medicines (IACM).
Below, you will find a selection of her key publications in the field:
Müller-Vahl, K. R., Schneider, U., Koblenz, A., Jöbges, M., Kolbe, H., Daldrup, T., & Emrich, H. M. (2002). Treatment of Tourette’s syndrome with Δ9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry, 35(02), 57-61.
Muller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M. (2003). D9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette Syndrome: A 6-Week Randomized Trial. Journal of Clinical Psychiatry, 64(4), 459-465.
Müller-Vahl, K. R., & Emrich, H. M. (2008). Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Review of Neurotherapeutics, 8(7), 1037-1048.
Grotenhermen, F., & Müller-Vahl, K. (2012). The therapeutic potential of cannabis and cannabinoids. Deutsches Ärzteblatt International, 109(29-30), 495.
Pringsheim, T., Okun, M. S., Müller-Vahl, K., Martino, D., Jankovic, J., Cavanna, A. E., … & Piacentini, J. (2019). Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology, 92(19), 896-906.
Kirsten R Müller-Vahl and others, Stop that! It’s not Tourette’s but a new type of mass sociogenic illness. Neurology, 92(19), 896-906.
Adán de Salas Quiroga is a biologist and specialist in Neurobiology. He obtained a Master’s degree in Biochemistry, Molecular Biology, and Biomedicine from the Complutense University of Madrid. In 2017, he received his Ph.D. from the same university, with a study on the role of the Endocannabinoid System during the development of the mammalian embryonic brain and the impact of prenatal exposure to this therapy. Adán has worked as a postdoctoral researcher in renowned national and international institutions, where he received additional training in electrophysiology and cancer.
Currently, he is dedicated to providing high-quality education to healthcare professionals and companies about cannabis and the endocannabinoid system.
Below is a selection of his main publications in the field:
de Salas-Quiroga, A., Díaz-Alonso, J., García-Rincón, D., Remmers, F., Vega, D., Gómez-Cañas, M., … & Galve-Roperh, I. (2015). Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB1 receptors on developing cortical neurons. Proceedings of the National Academy of Sciences, 112(44), 13693-13698.
Díaz-Alonso, J., de Salas-Quiroga, A., Paraíso-Luna, J., García-Rincón, D., Garcez, P. P., Parsons, M., … & Galve-Roperh, I. (2017). Loss of cannabinoid CB1 receptors induces cortical migration malformations and increases seizure susceptibility.
de Salas-Quiroga, A., García-Rincón, D., Gómez-Domínguez, D., Valero, M., Simón-Sánchez, S., Paraíso-Luna, J., … & Galve-Roperh, I. (2020). Long-term hippocampal interneuronopathy drives sex-dimorphic spatial memory impairment induced by prenatal THC exposure. Neuropsychopharmacology, 45(5), 877-886.
MD, neurologist, psychopharmacologist, researcher, and author, Ethan Russo is an unparalleled figure in scientific research on medical cannabis. For over 20 years, Ethan has dedicated his studies to exploring the therapeutic potential of the cannabis plant. He has authored numerous articles, books, and book chapters in the field, establishing himself as one of the pioneering physicians to systematize this knowledge worldwide. With over 50 scientific articles published in the field, he has made significant contributions to the education of Endocannabinoid Medicine in more than 30 countries.
From 2003 to 2014, Ethan served as the Medical Senior Advisor for the British pharmaceutical company GW. During this time, he actively participated in several phase I-III clinical studies of Sativex® Sativex® is a THC and CBD-based formulation registered in dozens of countries for its effectiveness in relieving pain associated with spasticity in multiple sclerosis. Additionally, Ethan played a vital role in the initial studies of Epidiolex®, a CBD-based drug registered by the FDA for the treatment of refractory epilepsies. Currently, Ethan serves as the founder and CEO of CReDO Science.
Below, you will find a selection of his key publications in the field:
Russo, E. (2001). Cannabis therapeutics in HIV/Aids. Psychology Press.
Russo, E. (2002). The Last Sorcerer: Echoes of the Rainforest. Psychology Press.
Russo, E., Dreher, M. C., & Mathre, M. L. (2002). Women and cannabis: Medicine, science, and sociology. Psychology Press.
Russo, E. (2003). Cannabis: from pariah to prescription. Psychology Press.
Grotenhermen, F., & Russo, E. B. (2006). Handbook of Cannabis Therapeutics: From Bench to Bedside;[a Compilation of Selected Articles from the Journal of Cannabis Therapeutics… from 2001 to 2004]. Haworth Press.
Russo, E. B. (2013). Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Routledge.
Russo, E. B., & Tyler, V. M. (2015). Handbook of psychotropic herbs: A scientific analysis of herbal remedies for psychiatric conditions.
Russo, E. B. (2019). The case for the entourage effect and conventional breeding of clinical cannabis: no “strain,” no gain. Frontiers in plant science, 9, 1969.
Russo, E. B., Plumb, J., & Whiteley, V. L. (2021). Novel solventless extraction technique to preserve cannabinoid and terpenoid profiles of fresh cannabis inflorescence. Molecules, 26(18), 5496.
MD, oncological surgeon, and mastologist. He holds a Master’s degree in Women’s Health and Breast Cancer from the Faculty of Medicine at UFMG. He is a former coordinator and currently serves as a Preceptor Physician for the Medical Residency Program in the Mastology Department at the Hospital das Clínicas of UFMG.
Since April 2014, he has been prescribing cannabis for medicalpurposes. He has extensive experience in providing adjunctive treatment to patients with epilepsy, autism, chronic pain, Alzheimer’s, Parkinson’s, autoimmune diseases, cancer, and in palliative care. He is also a medicinal cannabis cultivator with a Safe Conduct for his son Benicio, who has Dravet Syndrome and severe Autism.
Currently, he holds the position of Scientific Medical Director at the Brazilian Medical Cannabis Patients Association (AMA+ME) and is involved in clinical research.
Giovanni Marsicano is undoubtely one of the most important researchers on the endocannabinoid system ever. He has published more than 150 scientific articles, often in the most renowed journals, such as Nature and Science. He is pioneer in the conditional mutagenesis of the CB1 cannabinoid receptor, which allowed to dissect some of the main roles of this receptor in brain function, publishing numerous seminal papers which are constantly referenced. Giovanni, Italian, is veterinarian by formation, but he was very soon fascinated by laboratory research rather than medical practice. After working some years in Italy on different subjects such as stem cells in farm animals or genetic models of xenotransplantation, in 1997 he moved to Germany (Max-Planck Institute of Psychiatrie, Munich) and turned his scientific interests to neurosciences, and in particular on the study of the physiological ad pathophysiological roles of cannabinoid CB1 receptors in the brain. In 2006, Giovanni Marsicano established his independent group at the NeuroCentre Magendie in Bordeaux (France), where he keeps on his work enthusiastically dedicated to the dissection of the roles of CB1 receptors in different cellular and subcellular locations in the brain. Using conditional mutagenesis approaches, he worked on the differential physiological and behavioral roles of CB1 receptors on brain inhibitory and excitatory neurons, and, more recently, on brain mitochondrial membranes and on astrocytes. The aim of his work is to contribute understanding the mechanisms of behavior, using the CB1 receptors as “tools” to penetrate the complexity of brain functions.
MD, neurosurgeon certified by the World Institute of Pain (WIP) for minimally invasive procedures in pain (Fellow of Interventional Pain Practice).
Technical director of NeuroVinci Clinic, where she oversees more than 2,000 patients applying Endocannabinoid Medicine.
Founder of WeCann Academy, a Global Community for studies in Endocannabinoid Medicine, which already has more than 3,000 physicians from various countries.
Creator and host of WeCann Summit.
MD, specialized in Orthopedics and Traumatology from the Federal University of Rio de Janeiro, Ricardo Ferreira has accumulated over ten titles in his field throughout his career.
These include being a specialist in Orthopedics and Traumatology certified by the Ministry of Education (MEC), the Brazilian Society of Orthopedics and Traumatology (SBOT), and the Brazilian Medical Association (AMB). He is a full member of the Brazilian Society of Orthopedics and Traumatology and the Brazilian Society of Spine Surgery.
He is also a member of the North American Spine Society (NASS) and an expert in Spine as well as a member of AO Spine International. Additionally, he holds a specialization in pain from the Brazilian Society for the Study of Pain and an MBA in Healthcare Management from COPPEAD.
Ricardo Ferreira is one of the pioneering doctors in the application of Endocannabinoid Medicine in Brazil.
Tina Horsted has over 30 years of experience in treating patients. She has received training and certification from SSAI (Scandinavian Society of Anaesthesiology and Intensive Care Medicine) in pain management. In 2018, she published the book “Medical Cannabis – Quality of Life and Pain Relief with Cannabis Medicine.”
Recently, as a founder of the Horsted Institute, Tina compiled data from 2016-2018 on over 2,400 chronic pain patients treated with medical cannabis. Below are some of her key publications in the field:
Below are some of her key publications in the field:
Hendricks, O., Andersen, T. E., Christiansen, A. A., Primdahl, J., Hauge, E. M., Ellingsen, T., … & Petersen, K. H. (2019). Efficacy and safety of cannabidiol followed by an open label add-on of tetrahydrocannabinol for the treatment of chronic pain in patients with rheumatoid arthritis or ankylosing spondylitis: protocol for a multicentre, randomised, placebo-controlled study. BMJ open, 9(6), e028197.
Bhaskar, A., Bell, A., Boivin, M., Briques, W., Brown, M., Clarke, H., … & Moulin, D. E. (2021). Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. Journal of cannabis research, 3, 1-12.
Horsted, T., Hesthaven, K. L., & Leutscher, P. D. C. (2023). Safety and effectiveness of cannabinoids to Danish patients with treatment refractory chronic pain—A retrospective observational real‐world study. European Journal of Pain, 27(2), 234-247.
Mara Gordon is a globally recognized leader in the field of Endocannabinoid Medicine.
With her background as a Process Engineer assisting Fortune 500 companies in creating intelligent software, she has applied her expertise to develop cannabis formulations and therapeutic dosing regimens for thousands of patients in California, USA.
Mara is dedicated to openly sharing her knowledge and expertise regarding the therapeutic benefits of the cannabis plant through lectures, courses, conferences, and TEDx Talks. She consistently advocates for serious and responsible positions within the cannabis industry, which she deeply cares about.
Her groundbreaking work with medical cannabis was recently featured in the documentary “Weed the People” by Ricki Lake and Abby Epstein, available on Netflix.
MD, researcher, and author, Franjo Grotenhermen is an international reference in Endocannabinoid Medicine. For over 20 years, Franjo has been studying the therapeutic potential of the Cannabis plant. He is the author of a series of articles, books, and book chapters on the clinical applications, pharmacology, and toxicology of cannabinoid derivatives, being one of the pioneering doctors in systematizing this knowledge worldwide. He is the founder of the International Alliance for Cannabinoid Medicines (IACM), the oldest and most relevant medical society in the world that promotes scientific understanding of Endocannabinoid Medicine.
His biography was portrayed in the documentary “The Doctor,” widely acclaimed at film festivals around the world.
Below is a selection of his main publications in the field:
Grotenhermen, F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical pharmacokinetics, 42, 327-360.
Grotenhermen, F., & Russo, E. (2002). Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Psychology Press.
Grotenhermen, F. (2004). Cannabinoids for therapeutic use: designing systems to increase efficacy and reliability American Journal of Drug Delivery, 2, 229-240.
Grotenhermen, F. (2007). The toxicology of cannabis and cannabis prohibition. Chemistry & biodiversity, 4(8), 1744-1769.
Grotenhermen, F., & Müller-Vahl, K. (2016). Medicinal uses of marijuana and cannabinoids. Critical Reviews in Plant Sciences, 35(5-6), 378-405.
MD, surgeon, graduated from the University of Barcelona in 1979. He worked for 38 years as an emergency physician and occupational physician. For the past 17 years, he has been studying and working in the field of Endocannabinoid Medicine.
He is the founder of Kalapa Clinic in Barcelona, Spain, the first medical consultancy in Europe specialized in Endocannabinoid Medicine.
Additionally, Mariano is an active member of the Spanish Observatory of MedicalCannabis and a founding member of the Clinical Society of Endocannabinology in Spain.
MD specializing in medical law from the Universidad Pontificia Bolivariana and a Master’s in HIV from the Universidad Rey Juan Carlos.
Paola has been utilizing cannabis as a therapeutic tool for eight years and has assisted over 5,000 patients.
Paola Pineda is a founding member of the Curativa group in Colombia, where she focuses on researching the therapeutic potential of the cannabis plant and possible synergies with other substances.
Click the button below to check out the complete WeCann Summit 2024 schedule
The best curated content from over 40 speakers, world-leading national and international references in Endocannabinoid Medicine.
The meeting point for peers from Brazil and around the world looking to update and innovate their medical practice
The most qualified trade fair for products and innovations with the main products and industries in the sector
All-inclusive food and a pleasant atmosphere to enjoy the event with peace of mind and network with colleagues.
Cocktails and closing show included, because you deserve to celebrate this educational immersion.
Hosted by the leading organization in medical education in endocannabinoid medicine.
Attendee Welcome Kit
Access to Conference halls (subject to capacity)
Lunch and coffee included during the 03 days of event
Access to the exhibition and innovation fair
Access to the Networking Cocktail
Access to exhibiting brands' experiences and activations
Simultaneous translation
Exclusive Experience+ Welcome KIT
Exclusive registration, without queues
Exclusive access to luggage and headgear
Access to the Experience Area, with more comfort, benefits and surprises
Experience Dinner with WeCann Experts and Summit Speakers
Voucher for the purchase of the Endocannabinoid Medicine Treatise (exclusive for non-students / WeCann students will have even more special conditions)
R$ 100 R$ 200Voucher for accommodation (when booked through the event's official agency)
5% 10%Voucher for annual subscription to the WeCann Community and clinical case discussions platform
R$ 497 R$ 997Attendee Welcome Kit
Access to Conference halls (subject to capacity)
Lunch and coffee included during the 03 days of event
Access to the exhibition and innovation fair
Access to the Networking Cocktail
Access to exhibiting brands' experiences and activations
Simultaneous translation
Exclusive Experience+ Welcome KIT
Exclusive registration, without queues
Exclusive access to luggage and headgear
Access to the Experience Area, with more comfort, benefits and surprises
Experience Dinner with WeCann Experts and Summit Speakers
Voucher for the purchase of the Endocannabinoid Medicine Treatise (exclusive for non-students / WeCann students will have even more special conditions) - R$ 200
Voucher for accommodation (when booked through the event's official agency) - 10%
Voucher for annual subscription to the WeCann Community and clinical case discussions platform - R$ 997
Attendee Welcome Kit
Access to Conference halls (subject to capacity)
Lunch and coffee included during the 03 days of event
Access to the exhibition and innovation fair
Access to the Networking Cocktail
Access to exhibiting brands' experiences and activations
Simultaneous translation
Exclusive Experience+ Welcome KIT
Exclusive registration, without queues
Exclusive access to luggage and headgear
Access to the Experience Area, with more comfort, benefits and surprises
Experience Dinner with WeCann Experts and Summit Speakers
Voucher for the purchase of the Endocannabinoid Medicine Treatise (exclusive for non-students / WeCann students will have even more special conditions) - R$ 200
Voucher for accommodation (when booked through the event's official agency) - 10%
Voucher for annual subscription to the WeCann Community and clinical case discussions platform - R$ 997
The International Alliance for Cannabinoid Medicines (IACM) is the world’s leading medical society focused on the preparation and dissemination of reliable information about endocannabinoid medicine.
For more than 20 years, the IACM has supported educational and research activities related to the medicinal use of cannabis and cannabinoid derivatives.
WeCann Academy is an international community and a training and educational center in endocannabinoid medicine, which brings together specialists of national and international prominence, in order to join scientific knowledge and practical experience in a highly qualified way.
Our aim is to build an active community through the exchange of experiences that promote new possibilities in medicine.
Our online events have already reached more than 30,000 physicians from 59 countries. In November 2023, we held the largest in-person event on endocannabinoid medicine in the world, the WeCann Summit, in Campinas-SP, attended by doctors from more than 50 specialties and practice areas.
We believe in safe, effective and accessible forms of endocannabinoid system-targeting treatments, seeking to minimize the suffering of patients with chronic and disabling diseases and promote well-being on a large scale.